| Literature DB >> 29980444 |
Sakae Homma1, Masashi Bando2, Arata Azuma3, Susumu Sakamoto4, Keishi Sugino4, Yoshiki Ishii5, Shinyu Izumi6, Naohiko Inase7, Yoshikazu Inoue8, Masahito Ebina9, Takashi Ogura10, Kazuma Kishi11, Tomoo Kishaba12, Takashi Kido13, Akihiko Gemma3, Yoshihito Goto14, Shinichi Sasaki15, Takeshi Johkoh16, Takafumi Suda17, Kazuhisa Takahashi18, Hiroki Takahashi19, Yoshio Taguchi20, Hiroshi Date21, Hiroyuki Taniguchi22, Takeo Nakayama14, Yasuhiko Nishioka23, Yoshinori Hasegawa24, Noboru Hattori25, Junya Fukuoka26, Atsushi Miyamoto11, Hiroshi Mukae27, Akihito Yokoyama28, Ichiro Yoshino29, Kentaro Watanabe30.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a disease of unknown etiology which accounts for a large proportion of cases of idiopathic interstitial pneumonia. It has a very poor prognosis with a 5-year survival rate of 30% or below, and so far there has been no guideline in Japan offering an established effective therapy based on evidence. In addition to the establishment of basic therapies, there is also an urgent need to establish therapies to deal with complications, as death occurs in many cases due to acute exacerbation or comorbid lung cancer. It was therefore decided to formulate a guideline in order to promote evidence-based clinical practice, to further improve the quality of medical treatment in the clinical setting, and to allow the benefits to be enjoyed by the public.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29980444 DOI： 10.1016/j.resinv.2018.03.003
Source DB: PubMed Journal: Respir Investig ISSN： 2212-5345